What was the overall market valuation of the US polycystic ovarian-syndrome market in 2024?

The overall market valuation was $665.0 Million in 2024. Read More

What is the projected market valuation for the US polycystic ovarian-syndrome market by 2035?

The projected valuation for 2035 is $1124.58 Million. Read More

What is the expected CAGR for the US polycystic ovarian-syndrome market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.89%. Read More

What were the revenue figures for the diagnosis segment in the US polycystic ovarian-syndrome market?

The diagnosis segment generated revenues of $200.0 Million to $320.0 Million from pelvic examinations, $250.0 Million to $400.0 Million from ultrasounds, and $215.0 Million to $404.58 Million from blood tests. Read More

What are the revenue projections for the treatment segment in the US polycystic ovarian-syndrome market?

The treatment segment is projected to generate revenues of $200.0 Million to $320.0 Million from oral contraceptives, $150.0 Million to $240.0 Million from antiandrogens, and $100.0 Million to $160.0 Million from insulin sensitizing agents. Read More

What is the revenue range for hospitals and clinics in the end-user segment of the US polycystic ovarian-syndrome market?

The hospitals and clinics end-user segment generated revenues ranging from $400.0 Million to $650.0 Million. Read More

How do ambulatory surgical centers contribute to the US polycystic ovarian-syndrome market?

Ambulatory surgical centers contributed revenues ranging from $265.0 Million to $474.58 Million in the end-user segment. Read More

What treatment options are available for patients with polycystic ovarian syndrome in the US market?

Available treatment options include oral contraceptives, antiandrogens, insulin sensitizing agents, antidepressants, anti-obesity medications, and surgical interventions. Read More

How does the US polycystic ovarian-syndrome market compare to other markets in terms of growth?

The US polycystic ovarian-syndrome market appears to be on a growth trajectory, with a projected CAGR of 4.89% from 2025 - 2035. Read More

US Polycystic Ovarian Syndrome Market

Q: Which companies are considered key players in the US polycystic ovarian-syndrome market?

Key players include Bayer AG, Merck KGaA, AbbVie Inc, Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd, AstraZeneca PLC, Novartis AG, and Pfizer Inc. Read More

ID: MRFR/HC/55281-HCR 200 Pages Rahul Gotadki Last Updated: September 17, 2026

US Polycystic Ovarian Syndrome Market Research Report By Diagnosis (Pelvic Examination, Ultrasound, Blood Tests) - Growth & Industry Forecast 2025 To 2035

US Polycystic Ovarian Syndrome Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.89%

2024 Market Size$ 665 Million

2025 Market Size$ 697.52 Million

2035 Market Size$ 1,124.58 Million

Key Players

Bayer AG

Merck KGaA

AbbVie Inc

Ferring Pharmaceuticals

Teva Pharmaceutical Industries Ltd

AstraZeneca PLC

Trends

Rising Awareness and Education
Advancements in Treatment Options
Integration of Digital Health Solutions

Opportunities

Rising Healthcare Expenditure
Increased Focus on Women's Health
Growing Demand for Personalized Medicine

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Diagnosis (USD Million)
  1. 4.1.1 Pelvic examination
  2. 4.1.2 Ultrasound
  3. 4.1.3 Blood tests
2. 4.2 Healthcare, BY Treatment (USD Million)
  1. 4.2.1 Oral Contraceptives
  2. 4.2.2 Antiandrogens
  3. 4.2.3 Insulin Sensitizing Agent
  4. 4.2.4 Antidepressant
  5. 4.2.5 Anti-Obesity
  6. 4.2.6 Surgery
3. 4.3 Healthcare, BY End-user (USD Million)
  1. 4.3.1 Hospitals & Clinics
  2. 4.3.2 Ambulatory Surgical Centers
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bayer AG (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck KGaA (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AbbVie Inc (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Ferring Pharmaceuticals (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca PLC (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis AG (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer Inc (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 US MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF HEALTHCARE
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF HEALTHCARE
8. 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
9. 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
11. 6.11 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
12. 6.12 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
13. 6.13 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY END-USER, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

US US Polycystic Ovarian Syndrome Market Segmentation

US Polycystic Ovarian Syndrome Market By Diagnosis (USD Million, 2025-2035)

Pelvic examination
Ultrasound
Blood tests

US Polycystic Ovarian Syndrome Market By Treatment (USD Million, 2025-2035)

Oral Contraceptives
Antiandrogens
Insulin Sensitizing Agent
Antidepressant
Anti-Obesity
Surgery

US Polycystic Ovarian Syndrome Market By End-user (USD Million, 2025-2035)

Hospitals & Clinics
Ambulatory Surgical Centers

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”